BOSTON--(BUSINESS WIRE)--Veristat, a leading Clinical Research Organization (CRO) announced today that Variance Development Partners, a private investment group focused on contributing growth capital to small to mid-sized firms providing services to developing pharmaceutical and medical device companies, has made a growth equity investment in the company. Variance Development Partners investment will enable Veristat to further enhance its market leadership position and provide resources to pursue growth opportunities.
